Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report)'s stock had its "buy" rating restated by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright's price objective indicates a potential upside of 225.44% from the company's previous close. HC Wainwright also issued estimates for Corvus Pharmaceuticals' FY2025 earnings at ($0.43) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.44 EPS.
Corvus Pharmaceuticals Trading Up 0.3 %
Shares of Corvus Pharmaceuticals stock traded up $0.01 during trading hours on Wednesday, reaching $3.38. The stock had a trading volume of 647,385 shares, compared to its average volume of 580,680. The stock's 50 day moving average is $4.61 and its 200 day moving average is $6.06. Corvus Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $10.00. The firm has a market capitalization of $217.19 million, a PE ratio of -3.63 and a beta of 0.91.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.06). As a group, sell-side analysts predict that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.
Hedge Funds Weigh In On Corvus Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in CRVS. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter worth about $47,000. Nwam LLC purchased a new position in shares of Corvus Pharmaceuticals in the third quarter valued at approximately $53,000. PKS Advisory Services LLC acquired a new stake in shares of Corvus Pharmaceuticals in the fourth quarter worth approximately $56,000. Alpine Global Management LLC purchased a new stake in shares of Corvus Pharmaceuticals during the fourth quarter worth approximately $62,000. Finally, ExodusPoint Capital Management LP acquired a new position in Corvus Pharmaceuticals in the 4th quarter valued at $72,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.
Corvus Pharmaceuticals Company Profile
(
Get Free Report)
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
See Also
Before you consider Corvus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.
While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
